Sarepta’s gene therapy is fully approved, but its stock has tanked. Here’s why
This story was first published in the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
Sarepta Therapeutics CEO Doug Ingram is upset about the company’s slumping stock price.
Investors who have interacted with him this summer, including during a whitewater rafting trip, told me Ingram has been venting his frustration to anyone who will listen. The full approval in June for Elevidys, Sarepta’s gene therapy for Duchenne muscular dystrophy, was a spectacular moment for the company and the trigger for an expanded commercial launch that will deliver years of growth, Ingram has argued. Yet the stock acts like it’s all gone…
